Co-Authors
This is a "connection" page, showing publications co-authored by STEPHEN GOTTSCHALK and MAKSIM MAMONKIN.
Connection Strength
0.337
-
Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood. 2022 12 22; 140(25):2684-2696.
Score: 0.057
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.055
-
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 01; 160:112-133.
Score: 0.053
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2021 07 01; 131(13).
Score: 0.051
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2019 Jul 02; 129(8):3464.
Score: 0.045
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.039
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.037